Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD ‐ L1 in melanoma
Molecular Oncology · 2026
DOI: 10.1002/1878-0261.70182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2026. Verfasst von Guus A Franken und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical BioSciences, Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Tetraspanins, Melanoma, B7-H1 Antigen, Cell Membrane. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council: Proof-of-Concept Grant, NWO Gravitation Programme IMAGINE!, KWF Kankerbestrijding.
Abstract (Originalsprache)
PD‐L1 is a key immune checkpoint ligand that suppresses antitumor immunity by engaging PD‐1 on T cells. While therapeutic blockade of PD‐L1/PD‐1 interactions has shown clinical benefit, many patients fail to respond, indicating modulation by other factors. Here, we identified a novel regulatory axis in which the membrane‐organizing protein tetraspanin‐4 (TSPAN4) modulates PD‐L1 in melanoma cells. Using cell surface proximity biotinylation coupled with mass spectrometry, we discovered that TSPAN4 physically associates with PD‐L1, with both proteins colocalizing on migrasomes and retraction fibers. Mechanistically, we show that TSPAN4 negatively regulates PD‐L1 protein levels by enhancing its degradation and restricting its lateral mobility at the plasma membrane. Loss of TSPAN4 stabilized PD‐L1, promoted its interaction with CMTM6, and increased PD‐L1 surface availability for PD‐1 binding. Functionally, TSPAN4 knockdown in melanoma cells led to more efficient immune checkpoint blockade through PD‐1 on T cells. This study identifies TSPAN4 as a negative regulator of PD‐L1 at the cell surface of melanoma cells suggesting that targeting TSPAN4 may offer a new therapeutic strategy to enhance immune checkpoint blockade in melanoma and other cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical BioSciences, Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Molecular Biology, Faculty of Science, Radboud University, Nijmegen, The Netherlands.
- Oncode Institute, Utrecht, The Netherlands.
- Division of Molecular Genetics, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
- BioSR Consultancy, Eindhoven, The Netherlands.
ORCID-Profile: Guus A Franken, Annemiek B van Spriel
Förderung
- European Research Council: Proof-of-Concept Grant
- NWO Gravitation Programme IMAGINE!
- KWF Kankerbestrijding
- ZonMw
Zitieren
APA
Franken, G. A., Abel Gutierrez, A., van Rossum, I., Spruijt, C. G., Vermeulen, M., van Mierlo, G., Scheijen, B., & van Spriel, A. B. (2026). Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD ‐ L1 in melanoma. Molecular Oncology. https://doi.org/10.1002/1878-0261.70182
Vancouver
Franken GA, Abel Gutierrez A, van Rossum I, Spruijt CG, Vermeulen M, van Mierlo G, et al. Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD ‐ L1 in melanoma. Molecular Oncology. 2026. doi:10.1002/1878-0261.70182
BibTeX
@article{Franken2026,
author = {Franken, Guus A and Abel Gutierrez, Andrea and van Rossum, Imke and Spruijt, Cornelia G and Vermeulen, Michiel and van Mierlo, Guido and Scheijen, Blanca and van Spriel, Annemiek B},
title = {Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD ‐ L1 in melanoma},
journal = {Molecular Oncology},
year = {2026},
doi = {10.1002/1878-0261.70182}
}
EUVIMED